{
  "doc_id": "RECOTESTMOLPOUM25_CBNPC_tests_moléculaires",
  "created_date": "2023",
  "country": "FR",
  "source_type": "clinical_guideline",
  "chunks": [
    {
      "heading": "",
      "text": "JANUARY ACTUA",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "SLEITNEREFER",
      "text": "TE",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "ER 2023",
      "text": "ALISATION 2024",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "/ Réfé",
      "text": "PA\nD’U",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "BR",
      "text": "EC NO / Ind",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "RO",
      "text": "O EL dic ue pre tie TIE UNON L L L l e c i s e c i n d e c i n c e n t h e c i n t h e c e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t h e n t",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "CER",
      "text": "THAT MOLECULAR TEST INDICATIONS FOR THE PRECISION TREATMENT PRESCRIPTIONS The National Cancer Institute (INCA) is the agency of health and scientific expertise in cancerology responsible for coordinating the fight against cancers in France. This document constitutes a repository of good practice and management in cancerology taken under Article 2 of Article L.1415-2 of the Code of Public Health and was submitted to the expert committees of the National Cancer Institute on 05/12/2022 and 11/02/25 (update). This health expertise was adopted by decisions of the President of the Institute No. 2025-05 dated 19/03/2025 and published in the Institute's Register of Administrative Acts1.",
      "start_page": 1,
      "end_page": 2
    },
    {
      "heading": "Coordination National Cancer Institute",
      "text": "Aurélie KROL, PhD, Department of Biology, Transfer and Innovations, Research and Innovation Pole Sophie LE RICOUSSE, PhD, Department of Biology, Transfer and Innovations, Research and Innovation Pole",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "NOTE TO READERS",
      "text": "In order to take account of the rapid developments in the field, the document was updated in 2024. In the conclusions, the modifications made to the original version are highlighted in turquoise (August 2024). This document should be cited as follows: © Patients with non-small cell bronchial cancer / Indications of molecular tests for the prescription of precision treatments / Reference of good practice, collection \"Recommendations and references\", National Cancer Institute, 2024 of the January 2023 document. This document is published by the National Cancer Institute, which holds the rights to do so. The information contained in this document can be reused when: 1) their re-use falls within the scope of Law No 78-753 of 17 July 1978, 2) this information is not altered and their meaning is distorted, and 3) their source and the source of the information.",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "SOMMAIRE",
      "text": "BACKGROUND .......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "ABBREVIATIONS",
      "text": "AAC: compassionate access authorization APA: authorisation for early access ADN: deoxyribonucleic acid ADNtc: tumour DNA circulating ALK: Anaplastic Lymphoma Kinase (tyrosine kinase) AMM: marketing authorisation ANSM: National Agency for the Safety of Drugs and RNA Health Products: ribonucleic acid BRAF: B-Raf Proto-Oncogene (serine/threonine kinase) BRCA1/2: BRCA1/2 DNA repair associated CAP: College of American Pathologists CBNPC: non-small cell bronchial cancer CHMP: Committee for Medicinal Products for Human Use (Committee for Medicinal Products for Human Use) CNAM: national malad insurance fund CPC: compassionate prescribing framework EGFR: Epidermal Growth Factor Receptor EMA: European Drug Agency ESCAT: ESMO Scale for Clinical Action o molecular Targets ESMO: European Society for Medical Oncolog FISH: fluorescent hybridization Authority",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "CONTEXTE",
      "text": "The evidence of molecular alterations in cancer cells has not only contributed to a better understanding of the mechanisms that have affected the development of the disease, but also to the development of therapies that target these molecular abnormalities. The molecular characterization of the tumour has thus become a determining criterion in the choice of therapeuhque strategy. It allows to restrict the prescriphon of a number of treatments to the above-mentioned pahents to benefit from it and thus to reduce the number of inuhles, toxic and costly treatments. Targeted therapies guided by biomarkers in non-small cell bronchial cancer In non-pehte cell lung cancer (NCPC), tyrosine kinase inhibitors (ITK) are consummating a major therapeuhque weapon in metasthacs. Since 2009, gefihnib has had a marketing autorisahon (AMM) for those pahents whose tumour carries an EGFR achvator mutahon.",
      "start_page": 5,
      "end_page": 6
    },
    {
      "heading": "Molecular tests for the identification of biomarkers",
      "text": "In the case of the analysis of solid tumours, a minimum list of 16 genes was published by INCa2 for routine use. DNA NGS (DNAseq) is not always sufficient to analyze all required biomarkers, and complementary techniques are deployed in clinical prahch, such as immunohistochemistry (IHC) for the study of protein expression such as PD-L1 and ALK, or NGS sequencing on RNA (RNAseq) for the research of fusion transcripts. Furthermore, while the investigation of these molecular anomalies is traditionally performed on the tumour tissue attached to formol and included in paraffin, an alternative biological source, commonly known as liquid biopsy, is increasingly used.",
      "start_page": 6,
      "end_page": 7
    },
    {
      "heading": "Update August 2024",
      "text": "In order to take account of rapid developments in the field, updates were made in 2024. Thus, the following elements were added or modified in the document: • the search for preoperative biopsy status PD-L1, ALK and EGFR for possible neoadjuvant immunotherapy of non-metastatic CBNPCs from stage IIA to IIIB immediately resectable (new MAH and AAP nivolumab + chemotherapy) (see paragraph A.1.); • the search for RET fusions made mandatory before starting the first treatment line at metastatic stage (new MAH selpercatinib) (see paragraph C.3.); • the search for overexpression of c-MET in IHC and MET amplification in molecular biology for advanced/metastatic non-epidermoids relapsed CBNPCs in the absence of EGFR mutation from the second treatment line (AAFC telisotuzumab vedotin) (see paragraph",
      "start_page": 7,
      "end_page": 10
    },
    {
      "heading": "1. For neoadjuvant treatment",
      "text": "For a non-metastatic CBNPC immediately resectable (IIA stages ≥ 4 cm to IIIB — 8th TNM), expressing PD-L1 at the threshold ≥ 1% and in the absence of an activating mutation of the EGFR and fusion of the ALK, it is possible to treat the patient by neoadjuvant with nivolumab in combination with chemotherapy based on platinum salts (AMM, PAA). Therefore, these biomarkers should be investigated as early as preoperative biopsy.",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "2. For adjuvant treatment",
      "text": "If the PD-L1, EGFR and ALK status have not already been determined on preoperative biopsy for the prescription of neoadjuvant therapy, the following research will be required: a. EGFR For patients in stages IB to IIIA with a completely resected tumour, the presence of a L858R mutation or deletion of l'exon 19 d-EGFR allows adjuvant treatment with l'osimmertinib for three years (MA; test recommended by ESMO and NCCN) after adjuvant chemotherapy when indicated.4 The search for mutations may be performed independently on preoperative biopsies or operating parts. b. PD-L1 and ALK The search for PD-L1 status is not indispensable. Indeed, an AMM has been granted to atezolizumab by adjuvant, after complete resection and platinum-based chemotherapy, for patients with a high risk of recurrence and tumour with a TPS (tumor proportion: percentage",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "To be monitored:",
      "text": "Research into ALK status may become necessary to consider adjuvant treatment with alectinib for patients from stage II to IIIA (intermediate results of the ALINA trial submitted to ESMO 20235). An AMM application was submitted to EMA. 4 Overall survival data from the princeps study ADAURA: Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB- IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. Herbst RS, et al., J Clin Oncol. 2023 Apr 1;41(10):1830-1840. doi: 10.120/JCO.22.02186. Epub 2023 Jan 31. PMID: 36720083 t For neoadjuvant treatment: Search for PD-L1, ALK and EGFR biomarkers as early as preoperative biopsy. For adjuvant treatment: For patients from stages IB to III may be necessary.",
      "start_page": 10,
      "end_page": 11
    },
    {
      "heading": "1. PD-L1",
      "text": "At the locally advanced stage, regardless of histology (epidermoid or non-epidermoid), the level of expression of PD-L1 by tumour cells should be evaluated (test recommended by the ESMO and NCCN). • For non-operable patients, whose TPS is greater than or equal to 1% and whose disease has not progressed after chemioradiotherapy, durvalumab is an option (MA); • For adult patients with locally advanced non-operable CBNPC whose disease has not progressed after platinum chemioradiotherapy, if the TPS is less than 1% or if this status is sought, but the result of this marker is not exploitable, durvalumab is also an option (AAFC); • For patients with a TPS greater than or equal to 1% and who have received at least prior chemotherapy, pembrolizumab is a locally advanced disease.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "2. EGFR",
      "text": "The decision to consolidate immunotherapy after chemoradiotherapy in case of oncogenic addiction, particularly mutation of the EGFR is discussed, knowing that the majority of the data do not show any benefit with durvalumab. It is recommended to search for mutations, including rare, of the EGFR (exons 18, 19, 20 and 21) in all patients in order to avoid prescribing inefficient, long and expensive immunotherapy (test recommended by the ESMO and NCCN). This research can be carried out preferentially by NGS or by targeted test, depending on the local organisation. The results of these analyses should be available before the end of the adjuvant chemotherapy.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "Conclusion",
      "text": "At the locally advanced non-resectable stage of CBNPC, it is essential to evaluate the level of expression of PD-L1 (squamous and non-squamous cancers) in the tumour and it is recommended to investigate the mutahons of EGFR (exons 18-21). The results of these analyses should be available before the end of adjuvant chemotherapy.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "C. Metastatic stage (stage IV)",
      "text": "At the metastatic stage, before starting the first treatment line, it is necessary to search for the PD-L1 status, the mutations of EGFR and the fusions of ALK, ROS1 and RET. In order to set up the treatment within a reasonable time, given the aggressiveness of some metastatic CBNPCs, the search for these biomarkers must be carried out quickly. The ideal time frame recommended from the diagnosis of anatomopathology is 7 calendar days, with a maximum of 14 days. In case of emergency, the identification of the main additive mutations (mutation L858R and deletion of l'exon 19) must be possible in a very rapid circuit. Moreover, the amount of tumour tissue available may be limited, the emphasis must be on efficient management of tumour tissue in order to be able to perform all the required immunohistochemical and molecular biology tests.",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "1. PD-L1",
      "text": "The PD-L1 status is to be evaluated by IHC (test recommended by ESMO, NCCN and NICE). IHC should be performed according to the recommendations of the anatomopathological discipline. This research should be carried out for all histological types (epidermoids and non-epidermoids). For patients with a TPS greater than or equal to 50%, and in the case of a lack of mutation of the EGFR and fusion involving the ALK gene, treatment with pembrolizumab, atezolizumab or cemiplimab (unreimbursed) is possible as monotherapy (MM). Pembrolizumab is also available to patients whose tumours express PD-L1 with a TPS greater than or equal to 1%, and who have received at least one previous chemotherapy (AMM).",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2. EGFR",
      "text": "The search for variants of the EGFR gene makes it possible to consider first-line anti-EGFR ITK treatments in monotherapy for patients with CBNPC with activation mutations of the EGFR. The prescription of the osimertinib is also possible in case of a T790M mutation of the EGFR (AMM; test recommended by the ESMO, the NCCN, CAP and NICE). In order to optimize the delays, in case of metastatic CBNPC of non-epidermoid type, the organization of the local circuit between clinicians and the health care services must allow the reflex prescription of this biomarker, from the moment of diagnosis. In case of identification of an addictive mutation of the EGFR, it is not useful to look for further additive alterations before the first line treatment, since these anomalies are largely mutually exclusive.",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "3. ALK, ROS1 and RET",
      "text": "The search for mergers involving ALK, ROS1 (tests recommended by L-ESMO, NCCN, CAP and NICE) and RET (tests recommended by ESMO, NCCN) must be carried out. The presence of a fusion involving ROS1 allows the prescription of crizotinib for adult patients with advanced CBNPC (AMM) (reimbursement in France from the second treatment line). The presence of a fusion involving RET allows for treatment with selpercatinib from the first treatment line (MAH with favorable notice from HAS for the refund). Prassetinib also has an MAH, but not yet a refund in France. The fusions of ALK and ROS1 can be sought first-intention by IHC or directly by RNAseq, if the delay of rendering of the results allows. L-IHC ALK with a 1+ or 2+ mark-up intensity must be confirmed by molecular technique (RNAseq, FISH or other). L-IHC ROS1 positive, regardless of the time allowed.",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "4. Multiplexed tests",
      "text": "If an NGS panel has not been performed at first intent and for second-line treatment, it is essential to complete the rapid search for mutations of the EGFR with multiplexed analysis of the NGS type, exhaustively analyzing mutations (including insertions of the exon 20) and fusions. This search can be done in one or two DNA and/or RNA panels, and concomitantly or sequentially if the overall time for rendering the results is met (if the NGS analysis is performed on DNA and there is no detectable additive abnormality, the search for fusions can be done by NGS on RNA). In order for the patient's treatment to start as soon as possible, the time for rendering the NGS test (DNA and/or RNA) must not exceed 3 calendar weeks. In case of identification of additive oncogenic mutation, it is not useful to look for further",
      "start_page": 13,
      "end_page": 16
    },
    {
      "heading": "1. Progression after targeted therapy",
      "text": "In case of progression of the disease under ITK, it is necessary to look for abnormalities of resistance to ITK in order to be able to prescribe other ITKs of subsequent generation or combination of ITKs. Depending on the drug for which there is resistance, it may be necessary to look for mutations of the EGFR, ALK, ROS1, KRAS, BRAF, ERBB2, RET fusions, MET amplifications (in particular in case of mutation of EGFR) and ERBB2, as they may be involved in resistance mechanisms (EGFR: tests recommended by NCCN, ESMO Precision Medicine Working Group, ESMO; broad genomic panel recommended by NCCN). These molecular anomalies are to be investigated by NGS (DNA and/or RNA), on a tissue sampling of progressive lesion. This new sampling will also allow to identify a possible histological transformation, which is part of the mechanisms of resistance identified.",
      "start_page": 16,
      "end_page": 17
    },
    {
      "heading": "Conclusions",
      "text": "At the metastatic stage, prior to the first treatment line, it is essential to search for the PD-L1 status (including for epidermoid CBNPC), mutations of EGFR and fusions of ALK, ROS1 and RET. Timing and management of the tumour tissue: • the recommended ideal rendering time of results is 7 days from the anatomopathological diagnosis, with a maximum of 14 days; • in case of emergency, identification of the main addictive mutations (mutation L858R and deletions of l'exon 19) must be possible in a very rapid circuit; • in case of non-epidermoid CBNPC, the organization of the local circuit between clinicians and the services of anatomopathology must allow the reflex prescription of these biomarkers, from the moment of diagnosis; • efficient management of the tumour tissue must be privileged, in order to be able to perform all the immunohistochemical and molecular biology examinations required.",
      "start_page": 17,
      "end_page": 18
    },
    {
      "heading": "Methodology",
      "text": "Data considered for the definition of indications This work is an expert opinion based on existing international recommendations, the granting of MAHs, PAAs and AAFCs, as well as on clinical trials opened in France. It was based on: • the clinical practice recommendations most recently published by major international issuers: ESMO, NCCN, NICE and ASCO (Annex 1 analysis): o Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnostics, treatment and follow-up – Ann Oncol (2023) volume 34, April 2023, pp358-376, o Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnostics, treatment and follow-up – Ann Oncol (2023) volume 34, April 2023, pp339-357, o Early and locally addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnostics, treatment and follow-up – Ann Oncol (2023) volume 34, April 2023, pp339-357, o Early and locally advanced non-small-cell cancer: ESMO Clinical (NSCLC)",
      "start_page": 19,
      "end_page": 20
    },
    {
      "heading": "National review in 2022",
      "text": "The paper prepared by the expert group was submitted to a national review. The rereading took place from 4 August to 18 September 2022. The professionals of the peer review group made a rating of each conclusion (SPHINX online questionnaire, prepared by the INCa). The following questions were asked: • Are you concerned with the recommendation? Answer: YES/NO • Do you agree with the recommendation? Response on a scale of 1 to 9 (1 being \"not at all agreed\" and 9 \"strongly agree\") • Do you find the applicable recommendation? Answer: YES/NO • The questionnaire ended with a question about the usefulness of the document and its clarity Response on a scale of 1 to 9 (1 being \"not at all agreed\" and 9 \"wholly agreed\") The rereaders all responded to all the questions.",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Early stage",
      "text": "Search for EGFR status (L858R and del19)",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Locally advanced stage",
      "text": "Research PD-L1 and EGFR (exons 18-21)",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Metastatic stage",
      "text": "Search status PD-L1 Search EGFR render time EGFR Reflex requirement EGFR for non-squad CBNPC Search ALK and ROS1 Panel NGS DNA and/or RNA Selection of mutations to be searched Choice of fusions to be searched Panel render time",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Progression after targeted therapy",
      "text": "Search for resistance anomalies by NGS Search for other emerging anomalies can be discussed in SPC Possible research on liquid biopsy",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Quality of the document",
      "text": "Clear Decision Tree Complete Decision Tree Useful Document Clear Document",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Update 2024",
      "text": "The annexes were updated in December 2023 (your international recommendations). A meeting with videoconference in January 2024 to decide the suis were to be amended, members of the advanced drafting group in the field were discussed and recommended following up until August 2024 validated the text changes are listed at the end of the introduction did not require a national rereading. Patients with non-small cell bronchial cancer: indicati",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Average % Responses ≥7",
      "text": "P 8.37 91.8 tables of the MAH, AAFC and PAA, and balance sheet of the drafters' group, have been carried out in accordance with the findings of some of the authors, which have updated their IPRs.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Participants",
      "text": "Group of experts forming the group of editors The members of the group are professionals concerned in their practice with the problem and wishing to contribute to this expertise. The leaders of the molecular g platforms of cancers, the Société de pneumonologie de langue française, the IFCT and the Société d'oncologie médicale were asked to propose experts. The group of experts is composed of anatomopathologists, biologists molécu d ́oncologists specializing in bronchial cancers.",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "Molecular Biologists and Pathologists",
      "text": "Professor Michèle BEAU-FALLER*, CHRU de Strasbourg Pr Marie BREVET, CHU de Lyon Dr Anne CAYRE*, Centre Jean Perrin, Clermont-Ferrand Dr Véronique DALSTEIN*, CHU de Reims Prof Marc DENIS*, CHU de Nantes Pr Lucie KARAYAN-TAPAN, CHU de Poitiers Dr Jacqueline LEHMANN-CHE*, APHP Saint-Louis, Paris Pr Antoinette LEMOINE*, APHP Paul-Brousse, Villejuif Dr Alexandra LESPAGNOL*, CHU de Rennes Dr Audrey MANSUET-LUPO*, APHP Cochin, Paris Dr Anne MC LEER*, CHU de Grenoble Pr Alain MOREL*, ICO Paul Papin, Angers Pr Jean-Christophe SABOURIN*, CHU de Rouen",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "Clinicians",
      "text": "Prof. Nicolas GIRARD*, Institut Curie, Paris Prof. Marie WISLEZ*, APHP Cochin, Paris Prof. Gérard ZALCMAN*, APHP Bichat, Paris",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "*Expert who participated in the update",
      "text": "Each expert participated intuitu personae and did not represent his or her own organisation. The Institute selected the experts based, inter alia, on the analysis of their curricula of their scientific productions, their declarations of interest (DPI) and, in the case of detailed information available on them in the Transparency — Health database.15 Experts declared that there were links of interest with one or more of the nine health industries which were the founders of the FIAC association.16 In the light of the points dealt with in the expertise, for each member of the group prior to their appointment and throughout the work, the Institute considered that 15 The public database Transparency - Health makes available information on the conveniences and benefits linking companies and health sector actors:",
      "start_page": 22,
      "end_page": 23
    },
    {
      "heading": "Group of rereaders in 2022",
      "text": "The members of the group are professionals concerned in their practice by and wishing to contribute to this expertise. Those responsible for the molecular platform of cancers, the Société française de pathology, the Oncological Cytogenomic Grouping, the Société de pneumonologie de langue França francophone de carcinologie thoracique and the Société française d'oncologie asked to propose members. The group of relecteurs is composed of 51 practitioners, molecular anatomopathologs, pneumonologists and oncologists specializing in bronchial cancers.",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "List of proofreaders",
      "text": "ANCEL Julien, pneumonologist, CHU Reims Dr AUDIGIER VALETTE Clarisse, pneumoncologist, CHITS Sainte Musse, Toulon Dr AUGER Nathalie, cytogenetics, Gustave Roussy, Villejuif Dr BELMONT Laure, pneumonologist, Centre Hospitalier Victor Dupouy, Argenteuil Pr BENNOUNA Jaafar, medical oncologist, Hôpital Foch, Suresnes Pr CADRANEL Jacques, pneumology, carcinogenic competence, AP-HP, Hôpital Te Pr CHENARD Marie-Pierre, pathological anatomy, Hôpital de Hautepierre, CHU d Pr CLAVEL CRAVOISIER Christine, pathology, genetics, CHU de REIMS Pr COPIN Marie-Christine, pathological anatomy, CHU dAngers Dr CORRE Romain, pneumoncologist, Centre Hospitalier de Cornouaille, Quimpe Pr CORTOT Alexis, pneumologist, CHU de Lille Pr COURCHAUD Sebas, pnemologist, Hospices Civils Civils, Hôpits Civils, CHômies CHôm, CHôm , CHôt, CHôt",
      "start_page": 23,
      "end_page": 24
    },
    {
      "heading": "ANNEXES",
      "text": "Annex 1. Clinical practice biomar Indication CBNPC at early stage CBNPC at metastatiq 25",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO 2023",
      "text": "NCCN 2024 CAP 2018",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO 2023",
      "text": "NCCN 2024 CAP 2018",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO 2023",
      "text": "NCCN 2024 CAP 2018",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO 2023",
      "text": "NCCN 2024 NCCN 2024",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO 2023",
      "text": "NCCN 2024",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO 2023",
      "text": "NCCN 2024 NCCN 2024",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO 2023",
      "text": "Amp Mut Mut CBNPC after progression of treatment with targeted therapy Pan Indication Biom Fusi CBNPC at the early stage Expr Amp CBNPC at the metastatic stage Alté 26",
      "start_page": 25,
      "end_page": 26
    },
    {
      "heading": "ESMO 2023",
      "text": "NCCN2024",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "ESMO 2023",
      "text": "NCCN 2024 CAP 2018 NICE 2019 NCCN 2024 Recommendations ESMO 2021 e) ESMO 2021 NCCN 2024 NCCN 2024 ecular Annex 2. AMM, AAC and AAP of m is guided by the status of a bioma (updated April 22, 2024, attention, the authorizations Biomarkers Molecules atezolizumab, pembrolizumab, cemplimab, durvaluma Expression PD-L1 nivolumab, tislelizumab erlotinib, gefitinib, afatinib, osimertinib Mutation activator d-EGFR dacomitinib ramucirumab3 Mobocertinib4, poziotin Mutation d-EGFR exon 20 amivantamab crizotinib, ceritinib, fusion involving ALK alecitinib, brigatinib, osimertinib Mutation involving ROS1 entrectinib repotrectinib Fusion involving NRK1/2/3 repotrectinibtation non-cababtation, abamtation abamnemnemnemnemnemnemnemnemnemnemnemnemnemnemnemnemnemnemnemnem",
      "start_page": 26,
      "end_page": 30
    },
    {
      "heading": "Merger involving ROS1",
      "text": "Is indicated as monotherapy in the treatment of adult patients with positive and advanced CCNPC crizotinib ROS1- CBNPC. Is indicated as monotherapy in adult patients with advanced forms of  entrectinib CBNPC positive for ROS1 (ROS1+), not previously treated with ROS1 inhibitors.1 Validation of the repotrectinib AMM application for the treatment of locally advanced or metastatic non-small cell lung cancer Ros1-Positive and solid Ntrk-Positive Repotrectinib tumours (discontinuation of 02/01/2024, pending publication by the EMA).",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "Merger involving RET",
      "text": "It is indicated as monotherapy in the treatment of adult patients with advanced CNSC selpercatinib with a fusion of the RET gene not previously treated with a RET inhibitor is indicated as monotherapy in the treatment of adult patients with advanced CNSC pralsetinib with a positive fusion of RET not previously treated with a RET inhibitor.",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "BRAF V600E mutation",
      "text": "trametinib are indicated in combination for the treatment of adult patients with advanced NSCLC and dabrafenib with BRAF V600E mutation.",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "KRAS G12C mutation",
      "text": "It is indicated as monotherapy in the treatment of adult patients with advanced CBNPC sotorasib, with the KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment line. It is indicated as monotherapy for the treatment of adult patients with advanced non-small cell bronchial adagrasib cancer (NCSC) with KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment.",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "Expression of PD-L1 (GST)",
      "text": "Is indicated as monotherapy in the adjuvant treatment of adult patients with a high risk of recidivism NSCLC after complete resection and platinum salts chemotherapy Is indicated as monotherapy in the first-line treatment of adult patients with metastatic NSCLC whose tumours express PD-L1 with tumour proportion score (TPS) 350%, without tumour mutations of EGFR or d-ALK. Is indicated in combination with pemetrexed chemotherapy and platinum salt, in the first-line treatment of adult patients with non-epidermoid metastatic NSCLC whose tumours do not exhibit mutations of D-EGFR or d-ALK. duravalu atezoliz 32-REFER Patien seen Is indicated in combination with carboplatin and paclitaxel or nab-paclitaxel, in the first-line treatment of adult patients with epidermoid metastatic NSCC Is indicated as monotherapy in the treatment of patients with",
      "start_page": 31,
      "end_page": 35
    },
    {
      "heading": "KRAS G12C mutation",
      "text": "Non-small cell advanced or metastatic bronchial cancer: in the presence of a mutation of KRAS p.G12C, having escaped a second line of treatment with",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "adagrasib (AAFC)",
      "text": "docetaxel or not eligible for docetaxel treatment. (Warning, potential risk of severe skin adverse reactions)",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "Mutation with leap of exon 14 MET",
      "text": "Treatment of adult patients with locally advanced or metastatic crizotinib NSCLC with c-MET l'exon 14 splicing site mutation after at least one platinum doublet treatment line with or without immunotherapy",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "MET amplification or c-MET expression",
      "text": "Advanced non-squamous/metastatic relapse/refractory NSCLC: telisotuzumab - in a therapeutic impasse after 2 treatment lines;",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "Vedotin (AAFC) - c-MET amplification or c-MET overexpression characterized by IHC;",
      "text": "- no EGFR mutation.",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "Fusion of ROS1",
      "text": "repotrectinib Non-small cell advanced bronchial or metastatic ROS1-positive cancer in patients with",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "Fusion of NTRK1/2/3",
      "text": "Solid tumours expressing a fusion of the NTRK1/2/3 gene, non-resectable metastatic repotrectinib or locally advanced, in patients who have already received a first line of",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "(AAC)",
      "text": "treatment.",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "Merger of RET",
      "text": "As monotherapy in the treatment of adult patients with advanced non-small cell bronchial cancer (NCBC) with fusion of the RET non-selpercatinib gene previously treated with a RET inhibitor only at the first treatment line.",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "Appendix 4: Early Phase Clinical Trials",
      "text": "The list of early-stage clinical trials open to inclusion in institutions with an early-stage labeled centre (CLIP2 2024-2029) is maintained on the following page: The list of trials requiring the search for a biomarker for the inclusion of patients for respiratory cancer, solid tumours and multilocations is available.",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "Early stage",
      "text": "CBNPC from IB to IIIA EGFR Complementary research after publication of international recommendations. Search: ((NSCLC) AND ((stage I) OR (stage II) OR (stage III) AND EGFR mutation) NOT (metastatic) Filters: Clinical Trial, Humans, English, French, from 2023 8 articles obtained: three articles were not selected because the stage investigated was IIIB-IV 5 articles selected and 1 article added by the experts: no result likely to evolve international recommendations 1. PMID: 37236398 Three-Year Safety, Tolerance, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. John T, Grohé C, Goldman JW, Shepherd FA, Marinis F, RS Kato T, Wang Q, Mel Botti Mopong, Choe",
      "start_page": 37,
      "end_page": 45
    },
    {
      "heading": "Main manufacturers of DM",
      "text": "FISH, IHC : Abcam, Cell Reporting Technology, Cliniscience, Bioc Biotechnology, Leica, Ménarini, Novocastra, Quartett Biochem Mutations, Fusions, NGS : Agilent, Amoy Diagnostics, Amplite Biotech, Blue DNA Companion, Cliniscience, Entrogen, Fluid Illumina, Invitae, Launch Diagnostics, Qiagen, Roche Diagnost Thermofisher, Pentabase, Precigenome, Sophia Genetic, Twist Patients with non-small cell bronchial cancer : indications of ricants d care, Diag micals, Roc ech, Bioca digm3B, G tics, Sigma t Bioscienc s tests mollec de d gnost che, V artis, Gene a Ald ce...",
      "start_page": 45,
      "end_page": 46
    },
    {
      "heading": "LEGISLATIVE DEPOSIT MARCH 2025",
      "text": "52MUOPLOMTSETOCER For more information",
      "start_page": 47,
      "end_page": 47
    },
    {
      "heading": "cancer.fr",
      "text": "Institut national du cancer 52, avenue André Morizet 92100 Boulogne-Billancourt France Tel.: +33 (1) 41 10 50 00",
      "start_page": 47,
      "end_page": 47
    },
    {
      "heading": "table underheading <CER> (column 1)",
      "text": "Row 1: JANVI ACTUA Row 2: SLEITNEREFER TE SNOITADAMMOCER Row 3:",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "table underheading <CER> (column 2)",
      "text": "Row 1: Row 2: ER 2023 ALISATION 2024 / Refé PA D的U BR NO CE / Ind seen from p Row 3:",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "table underheading <CER> (column 3)",
      "text": "Row 1: Row 2: Ere AT 的U RO O EL dic u pre Row 3:",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "table underheading <CER> (column 4)",
      "text": "Row 1: Row 2: fit TIE ONE ON ON LL catio e de écisi Row 3:",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "table underheading <CER> (column 5)",
      "text": "Row 1: Row 2: and good ENTS N CAN NCH N TO BE LULES on yours command Row 3:",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "table underheading <CER> (column 6)",
      "text": "Row 1: Row 2: es prat S AT NC HQ ETI S ests m iption Row 3:",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "table underheading <CER> (column 7)",
      "text": "Row 1: Row 2: Ticks ATTEINTS CER que ITES moleculares n de treatmentes Row 3:",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "table underheading <Update August 2024>",
      "text": "Row 1:-This document presents the findings of the expert group on the testing strategy to be put in Row 2:-placed in patients with NSCLC for optimal care strategy at all stages of Row 3:--disease (considering the data available at the time of writing of the document)--addressed Row 4:--to all molecular test prescribers to guide the choice of tests to be performed for their Row 5:--patients (e.g., oncologist, pneumonologist or other clinician) and practitioners who perform these tests-- Row 6:--(anatomopathologists and biologists).-- Row 7:--Attention, the purpose of this document is to recommend the tests to be performed and not the treatments-- Row 8:--to be administered.- Treatments are discussed to explain the relevance of the tests, but the list of Row 9:-----therapeutic choices for patients is not exhaustive.",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <Conclusion>",
      "text": "Row 1::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "table underheading <Conclusion>",
      "text": "Row 1:的Conclusions:How to use a local, non-resectable advanced stage of CBNPC is essential to evaluate the level of PD-L1 (squamous and non-squamous cancers) in the tumour, and it is recommended to search for mutahons from EGFR (examples 18 to 21).",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "table underheading <4. Multiplexed tests> (from previous page)",
      "text": "Row 1:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "table underheading <Conclusions>",
      "text": "Row 1:的Conclusions:ssevere:ssevere:ssevere:ssevere:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:severe:several:severe:severe:severe:s:severe:severe:s:severe:s:severe:s:severe:s:severe:s:s:severe:s:s:s:severe:s:s:severe:s:s:s:s:s:s:s:s:s:s:s:s",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "table underheading <Conclusions> (from previous page)",
      "text": "Row 1:的If a multiplexed NGS panel was not performed for first purpose and in anticipation of the treatment of Row 2:的second line, it is essential to complete the rapid test with a multiplexed analysis of Row 3:的type NGS looking for mutations and fusions.",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "table underheading <Average % Responses ≥7>",
      "text": "Row 1:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "table underheading <Average % Responses ≥7> (column 1)",
      "text": "Row 1 : Early stage",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "table underheading <Average % Responses ≥7> (column 1)",
      "text": "Row 1 : Locally advanced stage",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "table underheading <Average % Responses ≥7> (column 1)",
      "text": "Row 1:--Metastatic Stade",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "table underheading <Average % Responses ≥7> (column 1)",
      "text": "Row 1:-Progress after targeted therapy",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "table underheading <Average % Responses ≥7> (column 1)",
      "text": "Row 1 : Quality of the document",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "table underheading <Average % Responses ≥7> (column 2)",
      "text": "Row 1:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "table underheading <ESMO 2023>",
      "text": "Row 1:的Indicatives & Biomarkers Essentials & Biomarkers & Biomarkers & Biomarkers & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks & Binomarks.",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "table underheading <ESMO 2023> (column 1)",
      "text": "Row 1:--Indication",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "table underheading <ESMO 2023> (column 2)",
      "text": "Row 1:---------------------------------------------------------------------------------------------------------------",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "table underheading <ESMO 2023> (column 6)",
      "text": "Row 1:-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "table underheading <ESMO 2023>",
      "text": "Row 1: CBNPC at metastatic stage: -Mutation MET ex 14 skip: -NCCN 2024 ESMO 2023 Row: -Amplification of MET/overexpression of c-MET: -ESMO 2023 Row: -Mutation HER2 (ERBB2): -ESMO 2023 NCCN2024 Row: - CBNPC after progression of treatment with targeted therapy: -Mutation EGFR T790 M-ESMO 2023 Row: -NCCN 2024 Row 6: -CAP 2018 Row 7: -NICE 2019 Row 8: -Large genomic analel: -NCCN 2024",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "table underheading <ESMO 2023>",
      "text": "Row 1:-Indication:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "table underheading <ESMO 2023> (column 1)",
      "text": "Row 1: CBNPC at the metastatic stage Row 2: CBNPC after progression of treatment with targeted therapy",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "table underheading <ESMO 2023> (column 1)",
      "text": "Row 1:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "table underheading <ESMO 2023> (column 5)",
      "text": "Row 1: NCCN 2024 ESMO 2023 Row 2: ESMO 2023 Row 3: ESMO 2023 NCCN2024 Row 4: ESMO 2023 Row 5: NCCN 2024 Row 6: CAP 2018 Row 7: NICE 2019 Row 8: NCCN 2024",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "table underheading <ESMO 2023> (column 5)",
      "text": "Row 1:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page)",
      "text": "Row 1: Biomarkers & Molecules & Molecules & Molecules & Molecules & Molecules – Type of authorizations & authorizations in France:How to access France:How to access France:How to access France:How to access France:How to access the CBNPC1:Row: Expressionion PD-L1:atezolizumab, pembrolizumab, cembrolimab, durvalumab2, nivolumab, tislelizumab, aftinib, aftinib, osimertinib, afreb, afreb, afreb, afreb, afreb, afreb, afreb, afreb, afreb, afreb, afreb, afreb, afreb, afreb, afreb, afreb, afreb, afreb, afreb, afrebreb, afrebreb, afrebre, afre, afre, afre, afrebrebre, afre, af, af, afre, afre af, afre afre afre a",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 1)",
      "text": "Row 1: Biomarkers-Mollicles-Row 2: Expression PD-L1 - Row 3: Activator mutation of EEGFR - Row 4:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 1)",
      "text": "Row 1 : entrectinib",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 2)",
      "text": "Row 1 : Type of authorization",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 2)",
      "text": "Row 1:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 2)",
      "text": "Row 1:--------------------------------------------------------------------------------------------------------------",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 2)",
      "text": "Row 1:",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 3)",
      "text": "Row 1: on-the-job access in Fran Row 2:--for CBNP",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 3)",
      "text": "Row 1:1:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 3)",
      "text": "Row 1:1:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 3)",
      "text": "Row 1 : No",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 4)",
      "text": "Row 1: nce-Row 2: PC1",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 4)",
      "text": "Row 1:-Row 2:-Row 3:--",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 4)",
      "text": "Row 1: |",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page)",
      "text": "Row 1: Mutation leading to a jump of c-MET-Cryzotinibs 14 or 14 in C-MET-Cryzotinibs 14 or C-MET-Cryzotinibs 14 or C-MET-Cryzotinibs 14 or C-MET-Cryzotinibs 14 or C-MET-Cryzotinibs 14 or C-MET-Cryzotinibs 14 or C-MET-Cryzotinibs 14 or C-MET-Cryzotinibs 14 or C-MET-MET-Cryzotinibs 14 or C-MET-Cryzotinibs 14 or C-MET-MET-Cryzotinibs 14 or C-MET-MET-Cryzotinibs",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 1)",
      "text": "Row 1: Mutation leading to a jump of xon 14 from c-MET",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 2)",
      "text": "Row 1:--AAC--Yes--Row 2:--AMM--No--Row 3:--AMM--No--Row 4:--AMA--Yes--Yes--Yes--Yes--Yes--Yes--Yes--Yes--Yes--Yes--Yes--Yes--Yes--Yes--Yes--",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page)",
      "text": "Row 1: Molecules--Row:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 1)",
      "text": "Row 1: Molécu-Row 2:-Mutatio Row 3: afatinib-Row 4: erlotini-Row 5: Gefitini-Row 6: osimert-Row 7: dacomi",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 2)",
      "text": "Row 1: ulles--Row 2:-AMM libel--Row 3:--Row 4: ons d--EGFR--Row 5: is indicated as monotherapy in the following treatments:- Row 6:- adult patients with locally advanced anti-EGFR---ITK--naïve patients with locally advanced CBNPC or-- Row 7:-metastatic patients with an EGFR--activating mutation(s);- Row 8:- adult patients with locally advanced or Row 9:-metastatic CBNPC, progressing on or after platinum-based chemotherapy.- Row 10: ib-Is indicated as:- Row 11:- first line of treatment for locally advanced or metastatic forms of Row 12:-CBNPC in patients with EGFR--activating mutations;- Row 13:- locally advanced or metastatic-form maintenance------Row 14:- of CBNPC---metastatic--forms in patients with first-grade mutations-------------------------------------------------------------------------",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page)",
      "text": "Row 1: ramucirumab, is indicated as follows:- Row 2:-- in combination with l-erlotinib, in the first-line treatment of adult patients, in combination with docetaxel, in the treatment of adult patients with non-small metastatic cells with mutations, in the treatment of non-small metastatic cells, in combination with mutations, in Row 4:-- in combination with docetaxel, in the treatment of adult patients with a locally advanced or metastatic non-small cell bronchial cancer whose Row 7:-- disease progressed after platinum-based chemotherapy.- Row 8: amivantamab, is indicated as monotherapy in the treatment of adult patients with a CBNPC, Row 9:--advanced with EGFR activation mutations by insertion into l-exon, after failure, Row 10:---amivantamab, is indicated as monotherapy in the treatment of adult patients with a CBNPC, Row 9:-----Advanced with activation mutations of EGFR by insertion into l-exon, 20, after failure, Row 10:----------------------------------------------------",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 1)",
      "text": "Row 1: crawling-up-- Row 2: amivan-- Row 3:-Fusion i Row 4: crizotin-- Row 5: ceritinib-- Row 6: alectini-- Row 7: brigatin-- Row 8: lorlatin---",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 2)",
      "text": "Row 1: Row 2: rumab Row 3: Row 4: Row 5: ntama Row 6: Row 7: implicate Row 8: Row 9: nib Row 10: Row 11: Row 12: b Row 13: Row 14: Row 15: ib Row 16: Row 17: Row 18: nib Row 19: Row 20: Row 21: nib Row 22:",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "table underheading <ESMO 2023> (from previous page, column 3)",
      "text": "Row 1: b-Identified as a single treatment for adult ALK patients with a CBNPC in combination with l的erlotinib, in the first-line treatment of adult patients, in the treatment of non-small metastatic bronchial cancer with mutations, in the treatment of adult patients with docetaxel, in the treatment of non-small metastatic bronchial cancer with mutations, in the treatment of adult patients with locally advanced or metastatic non-small cells, in the treatment of which the Row 7 disease has progressed after platinum-based chemotherapy, in combination with docetaxel, in the treatment of adult patients with CBNPCs, in the treatment of patients with Row 9:",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "table underheading <Expression of PD-L1 (TPS)>",
      "text": "Row 1:-Fusion involving ROS1--positive and advanced is indicated as monotherapy in adult patients with advanced forms of CBNPC:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "table underheading <Expression de PD-L1 (TPS)> (from previous page)",
      "text": "Row 1:的Is indicated in combination with carboplatin and paclitaxel or nab-paclitaxel, in Row 2:的the first-line treatment of adult patients with metastatic CBNPC Row 3:",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "table underheading <Expression de PD-L1 (TPS)> (from previous page, column 1)",
      "text": "Row 1: Row 2: Durvalu Row 3: atezolitz",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "table underheading <Expression de PD-L1 (TPS)> (from previous page, column 2)",
      "text": "Row 1:的Is indicated in combination with carboplatin and paclitaxel or nab-paclitaxel, in Row 2:的the first-line treatment of adult patients with metastatic CBNPC Row 3:",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "table underheading <Expression de PD-L1 (TPS)> (from previous page)",
      "text": "Row 1: cemiplimabs is indicated as monotherapy for the treatment of first-line adult patients in patients with a CCNPC expressing PD-L1 (in ≥ 50 % of tumour cells) without alterations in Row 3:, of the EGFR, ALK or ROS1 gene, who have:- Row 4:, of a locally advanced CCNPC and are not candidates for radio-chemiotherapy; or- Row 5:, of a metastatic CCNPC.- Row 6:, of a CCNPC is indicated in combination with platinum-based chemotherapy for Row 7:, of a first-line treatment of adult patients with bronchopulmonary cancer;- Row 8:, of a small cell (CBNPC) expressing PD-L1 (in ≥ 1 % of tumour cells) without Row 9:, of an EGFR, ALK or ROS1 gene, and who have:- Row 10:, of a CCNPC expressing PD-L1 (in ≥ 1 % of tumour cells) without alteration of the EGFR, ALK or ROS1 gene, and who have:-Row 10, of a meta-, of a CCNPC, of a locally advanced, or not a radio, or a radio, or radio, of a locally advanced.",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "table underheading <Expression de PD-L1 (TPS)> (from previous page, column 1)",
      "text": "Row 1: Cemipli-Row 2: nivolum-Row 3: tislelizu-Row 4:-Fusion i Row 5: larotrec-Row 6: Repotre",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "table underheading <Expression de PD-L1 (TPS)> (from previous page, column 2)",
      "text": "Row 1: Row 2: imab Row 3: Row 4: Row 5: mab Row 6: Row 7: Row 8: umab Row 9: Row 10: implication Row 11: Row 12: ctinib Row 13: Row 14: Row 15: ectinib Row 16:",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "table underheading <Expression de PD-L1 (TPS)> (from previous page, column 3)",
      "text": "Row 1:的Is indicated as monotherapy for the first-line treatment of adult patients, including patients who have been met with a CBNPC expressing PD-L1 (in ≥ 50% of tumour cells) without alterations, including: - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "table underheading <Expression de PD-L1 (TPS)> (from previous page)",
      "text": "Row 1:的(METex14), which requires systemic treatment after prior treatment with Row 6:的immunotherapy and/or platinum-based chemotherapy.:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "table underheading <Expression de PD-L1 (TPS)> (from previous page)",
      "text": "Row 1: trastuzumab Row 2: deruxtecan",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "table underheading <Expression de PD-L1 (TPS)> (from previous page)",
      "text": "Row 1: Molecules - L1 (TPS) - Row 5: durvalumab - Treatment of adult patients with locally advanced, non-operable NSCLC and - Row 6 - whose disease has not progressed after platinum-based chemoradiotherapy, in case - Row 7 - or - tumour expression of PD-L1 < 1% or if this status is sought, but - Row 8 - or - result of this marker is not exploitable (status unknown). - Row 9 - nivolumab - In combination with platinum-based chemotherapy in treatment - Row 10 - neoadjuvant of adult patients with non-small cell bronchial cancer - Row 11 - or - in combination - Row 9 - nivolumab - In combination with platinum-based chemotherapy in treatment - Row 10 - neoadjuvant of adult patients with non-small cell bronchial cancer - Row 11 - or - - known high-risk of recidivism - do not mutation - or - do not mutation - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "table underheading <Expression de PD-L1 (TPS)> (from previous page, column 1)",
      "text": "Row 1:的Mutatio Row 2: capmat, Row 3: tepotin, Row 4:的Mutatio Row 5: trastuzu deluxe,",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "table underheading <Expression de PD-L1 (TPS)> (from previous page, column 1)",
      "text": "Row 1: trastuzu Row 2: delusion",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "table underheading <Expression de PD-L1 (TPS)> (from previous page, column 1)",
      "text": "Row 1: Molecule-Row 2:-Express Row 3: durvalu-Row 4: nivolum-Row 5:-Mutatio-Row 6: moboce",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "table underheading <Expression de PD-L1 (TPS)> (from previous page, column 2)",
      "text": "Row 1: on skipping from 14 c-MET------ -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "table underheading <Expression de PD-L1 (TPS)> (from previous page, column 2)",
      "text": "Row 1: umab Row 2: auction",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "table underheading <Expression de PD-L1 (TPS)> (from previous page, column 2)",
      "text": "Row 1: ulles-L1 (TPS) - Row 5: umab-based treatment of adult patients with locally advanced, unoperable CBNPC and - Row 6: whose disease has not progressed after platinum chemoradiotherapy, in case Row 7:supplier expression of PD-L1 < 1%, or in case this status is sought, but Row 8:supplier result is not exploitable (status unknown) - Row 9: mab-in combination with platinum-based chemotherapy in treatment Row 10:neoadjuvant adult patients with non-small cell bronchial cancer - Row 11:resectable to high risk of recurrence, whose tumours express PD-L1 at ≥ 1% and -Row 12:supplier known mutation:Row 12:supplier known mutation:Row 1: ulles-L1 (TPS) - Row 1: ulles-L1 (TPS) - Row 5: umab-labelled early and compassionate access authorizations",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "table underheading <RET Fusion>",
      "text": "Row 1: amivantamabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsabsa",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "table underheading <RET Fusion>",
      "text": "Row 1: telisotuzumab Row 2: vedotin (AAFC)",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "table underheading <RET Fusion>",
      "text": "Row 1: repotrectinib Row 2: (AAFC)",
      "start_page": 35,
      "end_page": 35
    }
  ]
}